年轻患者BI-RADS 3病变的首次超声诊断:6个月随访是否足以评估稳定性
该回顾性研究纳入492例18-34岁首次乳腺超声检查的女性,其中97例共151个BI-RADS 3病变。6个月随访时15.3%降级为BI-RADS 1/2,7.1%升级为BI-RADS 4(活检率7%,阳性预测值44.4%);18个月随访时仅1个病变升级为BI-RADS 4(活检率1.1%,阳性预测值0%)。作者初步认为6个月随访可能足以评估可能良性病变的稳定性。
要点
- 年轻患者首次超声发现的BI-RADS 3病变,6个月随访中7.1%升级为BI-RADS 4,活检阳性预测值44.4%。
- 18个月随访仅1个病变升级为BI-RADS 4,活检阳性预测值0%,未影响临床处理。
- 作者认为6个月随访可能足以评估可能良性病变的稳定性。
核心结论
- 作者初步数据显示,首次BI-RADS 3诊断后18个月随访影像不影响临床治疗,6个月随访可能足以评估可能良性病变的稳定性。
研究设计与样本
- IRB批准的回顾性研究,纳入2012-2014年首次乳腺超声检查的492例18-34岁女性(平均28±4.5岁),其中97例共151个BI-RADS 3病变符合纳入标准。
诊断标准与关键数值
- 6个月随访时23/126(15.3%)降级为BI-RADS 1/2,9/126(7.1%)升级为BI-RADS 4(活检率7%,阳性预测值44.4%);18个月随访时1个病变升级为BI-RADS 4(活检率1.1%,阳性预测值0%)。
临床应用与阅片要点
- 作者认为6个月随访可能足以评估年轻患者首次超声发现的BI-RADS 3病变的稳定性,18个月随访影像不影响临床治疗。
局限性
- 原文结论中表述为「初步数据」,提示结果需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the outcome of repeated short-term follow-up with ultrasound in no high-risk young patients with a BI-RADS3 lesion at first examination.
METHODS: In this IRB-approved study 492 women, aged 18-34 years (mean±standard deviation, 28±4.5years) with first breast ultrasound examination in 2012-2014 were retrospectively evaluated. Inclusion criteria were: at least one BI-RADS3 lesion and (a) biopsy/surgical excision or (b) follow-up of at least 18 months (including a 6-month follow-up). BI-RADS category assigned during follow-up and pathologic findings in cases undergoing biopsy/surgical excision were collected. At the 6- and 18-month follow-up the recommended biopsy rates (RBR) and the corresponding positive predictive value (PPV) were calculated.
RESULTS: In 97 patients, 151 BI-RADS3 lesions were identified. Biopsy/surgical excision was initially performed in 25/151 (16.5%) lesions. After 6-month, category was downgraded to BI-RADS1/2 in 23/126 (15.3%) and upgraded to BI-RADS4 in 9/126 lesions (7.1%). Pathological diagnosis of these lesions was fibroadenoma in 5 and benign phyllodes tumor in 4 cases (RBR 7%, PPVbio 44.4%). After 18-month one lesion was classified BI-RADS4 and pathological diagnosis was fibroadenoma (RBR 1.1%, PPVbio 0%).
CONCLUSIONS: Our preliminary data show that follow-up imaging performed after 18 months from a first BI-RADS3 diagnosis does not affect clinical treatment and 6-month follow-up may be sufficient to assess the stability of probably benign lesions.
引用
- Marcon M, Frauenfelder T, Becker AS, et al. First ultrasound diagnosis of BI-RADS 3 lesions in young patients: Can 6-months follow-up be sufficient to assess stability? Eur J Radiol. 2017. PMID: 28267544. doi:10.1016/j.ejrad.2017.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。